DR
Therapeutic Areas
Lantern Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LP-300 | Relapsed advanced primary adenocarcinoma of the lung (Never-smokers with NSCLC) | Phase 2 |
| LP-184 | Multiple cancers with DNA Damage Repair deficiencies (e.g., Glioblastoma, Pancreatic Cancer) | Phase 1 |
| LP-284 | High-grade B-cell lymphomas, Soft Tissue Sarcoma, other DDR-deficient cancers | Phase 1 |
| ADC Program | Undisclosed solid tumors | Discovery/Preclinical |